The imidazoquinolines - Mechanism of action and therapeutic potential in HPV-associated disease

Papillomavirus Report

Volumn 16, Issue 3, 2005, Pages 141-146

  Stanley, Margaret A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HPV associated disease; Imidazoquinolines; Imiquimod; Therapy

Indexed keywords

ALPHA INTERFERON; GUANOSINE DERIVATIVE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 6; PLACEBO; RESIQUIMOD; S 27609; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VACCINE;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HERPES SIMPLEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PROTEIN INTERACTION; REVIEW; SKIN INFECTION; SKIN TUMOR; TH1 CELL; VIRUS INFECTION; WART VIRUS;

HERPES; HUMAN PAPILLOMAVIRUS TYPES;

EID: 20744452800     PISSN: 09574190     EISSN: None     Source Type: Journal    
DOI: 10.1179/095741905X41267     Document Type: Review

References (50)

1. Medzhitov R, Janeway Jr CA. Decoding the patterns of self and non-self by the innate immune system. Science 2002;296:298-300.
2. Boehme KW, Compton T. Innate sensing of viruses by Toll-like receptors. J Virol 2004;78:7867-73.
3. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9.
4. Diebold SS, Kaisho T, Hemmi H, Akira S, Reise Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31.
5. Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara™). Exp Opin Invest Drugs 98;7:437-49.
6. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21.
7. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-33.
8. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200.
9. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003;121:1205-9.
10. Schon MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004;122:1266-76.
11. Stanley MA. Mechanism of action of imiquimod. J Papillomavirus Report 99;10:23-9.
12. Stanley MA. Imiquimod and the imidazoquinolines: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571-7.
13. Harrison CJ, Jenski L, Voychehovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection [published erratum appears in Antiviral Res 1989;11:215]. Antiviral Res 88;10:209-23.
14. Bernstein DI, Harrison CJ. Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrob Agents Chemother 89;33:1511-5.
15. Weeks CE, Reiter MJ. Antiviral/immunomodulator R-837 induces α interferon in mice. J Invest Dermatol 89;93:584.
16. Gibson SJ, Elrod SV, Miller RL, Weeks CE. Oral R-837 induces a interferon in cynomologous monkeys. J Interteron Res 90;10(Suppl 1):S124.
17. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 94;55:234-40.
18. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RM, Miller RL et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 98;110:734-9.
19. Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, Miller RL et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 95;15:537-45.
20. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 95;58:365-72.
21. Kono T, Kondo S, Pastore S, Shivji GM, Tomai MA, McKenzie RC et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 94;13:71-6.
22. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 99;191:10-9.
23. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002;3:499.
24. - dendritic cells. J Immunol 2003;171:1156-63.
25. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002;218:74-86.
26. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174:1259-68.
27. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 98;178:551-5.
28. Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 2004;22:1782-90.
29. Zuber AK, Brave A, Engstrom G, Zuber B, Ljungberg K, Fredriksson M et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 2004;22:1791-8.
30. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004;173:3051-61.
31. Harrison CJ, Miller RL, Bernstein DI. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001;19:1820-6.
32. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005;174:2476-80.
33. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M et al. Immunological events in regressing genital warts. Am J Clin Pathol 94;102:768-74.
34. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA et al. Intiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135-41.
35. Beutner KR, Tyring SK, Trofatter Jr KF, Douglas Jr JM, Spruance S, Owens ML et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 98;42:789-94.
36. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas Jr JM. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 98;38:230-9.
37. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 98;134:25-30.
38. Laffort C, Le Deist F, Favre M, Caillat Zucman S, Radford Weiss I, Debre M et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gamma cytokine receptor subunit or JAK-3 deficiency. Lancet 2004;363:2051-4.
39. Hengge UR, Esser S, Schultewolter T, Behrendt C, Meyer T, Stockfleth E et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000;143:1026-31.
40. Harwood CA, Perrett CM, Brown VL, Leigh IM, McGregor JM, Proby CM. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol 2005;152:122-9.
41. Meyer T, Arndt R, Nindl I, Ulrich C, Christophers E, Stockfleth E. Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transpl Int 2003;16:146-53.
42. Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55.
43. Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol 2002;85:67-70.
44. Jayne CJ, Kaufman RH. Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod. J Reprod Med 2002;47:395-8.
45. Wendling J, Saiag P, Berville Levy S, Bourgault Villada I, Clerici T, Moyal Barracco M. Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. Arch Dermatol 2004;140:1220-4.
46. Kreuter A, Hochdorfer B, Stucker M, Altmeyer P, Weiland U, Conant MA et al. Treatment of anal intraepithelial neoplasia in patients with acquired HIV with imiquimod 5% cream. J Am Acad Dermatol 2004;50:980-1.
47. Stanley MA. Human papillomavirus vaccines. Curr Opin Mol Ther 2002;4:15-22.
48. Urosevic M, Oberholzer PA, Maier T, Hafner J, Laine E, Slade H et al. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin Cancer Res 2004;10:4959-70.
49. Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002;205:135-8.
50. Ugurel S, Wagner A, Pfohler C, Tilgen W, Reinhold U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002;147:621-4.